Biocon Limited

NSEI:BIOCON 株式レポート

時価総額：₹697.3b

Biocon 将来の成長

Future 基準チェック /46

Biocon利益と収益がそれぞれ年間47.6%と13.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に5.7% 44.5%なると予測されています。

主要情報

47.6%

収益成長率

44.49%

EPS成長率

Biotechs 収益成長35.2%
収益成長率13.1%
将来の株主資本利益率5.68%
アナリストカバレッジ

Good

最終更新日21 May 2026

今後の成長に関する最新情報

分析記事 • Aug 10

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...
分析記事 • Jun 19

Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...

Recent updates

分析記事 • May 21

Biocon's (NSE:BIOCON) Weak Earnings May Only Reveal A Part Of The Whole Picture

The subdued market reaction suggests that Biocon Limited's ( NSE:BIOCON ) recent earnings didn't contain any surprises...
ナラティブの更新 • May 03

BIOCON: Leadership Changes And Biosimilars Expansion Will Support Future Upside

Biocon's analyst price target has been trimmed slightly to about ₹416 from roughly ₹421 as analysts factor in a marginally higher discount rate, slightly softer revenue growth and profit margin assumptions, partly balanced by a modestly higher future P/E multiple. Analyst Commentary Recent Street research around comparable life sciences names points to a cautious tone on execution risk, revenue trajectory and the willingness of the market to pay up for growth after guidance disappointments.
ナラティブの更新 • Apr 19

BIOCON: Higher Profitability Assumptions Will Support U.S. Biosimilars And GLP-1 Entry

Narrative Update on Biocon Analysts have adjusted their price target on Biocon to ₹544, up from ₹465. This reflects updated assumptions around a higher fair value estimate, revised profit margin expectations, and a slightly different discount rate and forward P/E framework.
ナラティブの更新 • Apr 05

BIOCON: Leadership Refresh And Biosimilars Integration Will Support Future Upside

Analysts have trimmed Biocon's fair value estimate slightly to ₹420.74 from ₹421.60, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts are treating the trimmed fair value estimate as a fine tuning of expectations rather than a major reset, with views split between what could support upside and what might cap near term returns.
ナラティブの更新 • Mar 21

BIOCON: Limited P/E Expansion Will Constrain Returns Despite New Metabolic Drug Approvals

Analysts have trimmed their Biocon price target slightly to about ₹295.70 from roughly ₹297.40, reflecting a modest recalibration of fair value, discount rate and long term assumptions for revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts trimming Biocon's fair value signal a more careful stance on what they are willing to pay for the shares today, given reassessed views on growth, profitability and valuation multiples.
ナラティブの更新 • Mar 07

BIOCON: Limited Multiple Expansion Will Constrain Returns Despite New GLP 1 Approvals

Narrative update Analysts have trimmed their Biocon price target slightly to about ₹297 from roughly ₹298, reflecting updated assumptions on discount rate, revenue growth, profit margins and future P/E multiples after recent sector research signalled a more cautious stance on multiple expansion. Analyst Commentary Bearish analysts looking at global life sciences peers have trimmed price targets after recent earnings misses and cautious forward commentary, and those moves are informing how some investors think about Biocon's risk and valuation setup.
ナラティブの更新 • Feb 21

BIOCON: Execution And Multiple Compression Risks Will Restrain Future Share Returns

Analysts have inched up their Biocon fair value estimate to about ₹298 per share from roughly ₹295, reflecting slightly lower discount rate assumptions, modestly softer revenue growth expectations, a somewhat stronger profit margin outlook, and a marginally reduced future P/E multiple. Analyst Commentary While the fair value adjustment for Biocon is modest, some bearish analysts are still flagging risks that could cap upside in the near term.
ナラティブの更新 • Feb 07

BIOCON: Equity Dilution And Biosimilars Review Will Pressure Future Returns

Analysts have slightly reduced their Biocon fair value estimate to ₹295.12 from ₹296.78, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News Biocon completed a follow on equity offering of equity shares worth ₹41.5b, issuing 112,664,585 common shares at ₹368.35 each under a Regulation S structure with a subsequent direct listing (company filing).
ナラティブの更新 • Jan 23

BIOCON: Biosimilars Reorganisation And GLP 1 Expansion Will Drive Future Upside

Analysts have nudged their fair value estimate for Biocon higher from ₹412.05 to ₹421.60, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Biocon completed a follow on equity offering of ₹41.5b, issuing 112,664,585 equity shares at ₹368.35 per share under Regulation S, followed by a subsequent direct listing (Key Developments).
ナラティブの更新 • Jan 09

BIOCON: Planned Capital Raise Will Likely Weigh On Future Shareholder Returns

Analysts have lifted their price target on Biocon from ₹290.00 to about ₹296.78, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E inputs in their models. What's in the News Shareholders approved amendments to Biocon's Articles of Association at the AGM held on December 31, 2025, signaling changes to the company's governing documents (Key Developments).
ナラティブの更新 • Dec 26

BIOCON: Future Equity Issuance Will Likely Pressure Shareholder Returns

Analysts have maintained their fair value estimate for Biocon at ₹290.00 per share, with only minor model adjustments to discount rate, revenue growth, and profit margin assumptions. These changes have resulted in no alteration to their overall price target, as they continue to view the company’s long term earnings profile as broadly intact.
分析記事 • Dec 25

Calculating The Fair Value Of Biocon Limited (NSE:BIOCON)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Biocon fair value estimate is ₹364 With ₹398 share price...
ナラティブの更新 • Dec 12

BIOCON: Future Share Dilution Risk Will Likely Pressure Returns

Analysts have raised their price target on Biocon from ₹277.50 to ₹290.00, reflecting higher anticipated revenue growth, improved profit margins, and a modestly re-rated future P E multiple despite a slightly higher discount rate. What's in the News Biocon is exploring strategic options for its biosimilars arm Biocon Biologics Limited, including a potential merger with the parent company in place of an IPO, with Morgan Stanley advising on value creation alternatives (Key Developments).
分析記事 • Dec 07

Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel

You may think that with a price-to-sales (or "P/S") ratio of 3.2x Biocon Limited ( NSE:BIOCON ) is a stock worth...
ナラティブの更新 • Nov 27

BIOCON: Global Expansion And Business Restructuring Are Expected To Balance Opportunities And Risks

Analysts have raised their price target for Biocon from ₹395.65 to ₹412.05. This change reflects updated expectations around key valuation inputs and profitability metrics.
分析記事 • Nov 19

Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)

The market rallied behind Biocon Limited's ( NSE:BIOCON ) stock, leading do a rise in the share price after its recent...
ナラティブの更新 • Nov 13

BIOCON: Revenue Outlook And Global Expansion Likely To Support Steady Performance

Analysts have raised Biocon's fair value price target from ₹376.70 to ₹395.65, citing improved revenue growth projections and profit margins as key drivers for the upgrade. What's in the News Biocon announced the public funding of YESAFILI (aflibercept), a biosimilar to EYLEA, on the Ontario Drug Benefit Formulary in Canada for retinal disease treatment.
ナラティブの更新 • Oct 05

Biosimilars Demand Will Unlock Global Market Opportunities

Analysts have lowered Biocon's price target slightly from ₹380.11 to ₹376.70, citing marginal adjustments in the discount rate and projected earnings metrics. Analyst Commentary Market watchers have weighed in on Biocon's valuation following the recent adjustment to its price target.
分析記事 • Sep 22

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price

Key Insights The projected fair value for Biocon is ₹577 based on 2 Stage Free Cash Flow to Equity Biocon's ₹369 share...
分析記事 • Aug 10

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...
分析記事 • Aug 04

Pinning Down Biocon Limited's (NSE:BIOCON) P/E Is Difficult Right Now

Biocon Limited's ( NSE:BIOCON ) price-to-earnings (or "P/E") ratio of 50.5x might make it look like a strong sell right...
分析記事 • Jun 19

Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...
分析記事 • Jun 18

Biocon (NSE:BIOCON) Will Pay A Dividend Of ₹0.50

The board of Biocon Limited ( NSE:BIOCON ) has announced that it will pay a dividend on the 5th of September, with...
User avatar
新しいナラティブ • Dec 12

Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability

Strategic cost improvements and production efficiencies are set to enhance margins and profitability in the generics segment.

業績と収益の成長予測

NSEI:BIOCON - アナリストの将来予測と過去の財務データ ( )INR Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
3/31/2029249,13321,93924,82747,1416
3/31/2028228,62819,94527,42741,52218
3/31/2027200,53413,69222,77538,09618
3/31/2026169,2703,85682319,940N/A
12/31/2025168,2746,042N/AN/AN/A
9/30/2025164,7584,85517,97341,592N/A
6/30/2025157,7073,850N/AN/AN/A
3/31/2025152,61710,13317,17940,612N/A
12/31/2024147,6188,043N/AN/AN/A
9/30/2024148,94114,39221,04540,368N/A
6/30/2024147,66015,808N/AN/AN/A
3/31/2024147,55710,22510,22329,539N/A
12/31/2023146,12512,002N/AN/AN/A
9/30/2023135,9994,984-6,24111,717N/A
6/30/2023124,5734,197N/AN/AN/A
3/31/2023111,7424,6271,26218,525N/A
12/31/202298,0913,881N/AN/AN/A
9/30/202290,4226,170-6,83611,543N/A
6/30/202285,6297,084N/AN/AN/A
3/31/202281,8406,484-7,48211,766N/A
12/31/202175,8006,727N/AN/AN/A
9/30/202172,6326,542-6,36612,763N/A
6/30/202171,7266,852N/AN/AN/A
3/31/202171,4317,405-5,86611,597N/A
12/31/202068,9135,996N/AN/AN/A
9/30/202067,5716,362-6,57610,484N/A
6/30/202065,7966,870N/AN/AN/A
3/31/202063,0057,771-5,53412,831N/A
12/31/201963,1508,385N/AN/AN/A
9/30/201961,0778,529N/A14,573N/A
6/30/201958,5659,919N/AN/AN/A
3/31/201955,1449,053N/A11,546N/A
12/31/201851,5518,220N/AN/AN/A
9/30/201846,7226,967N/AN/AN/A
6/30/201843,1984,108N/AN/AN/A
3/31/201841,2343,724N/A6,621N/A
12/31/201738,7923,695N/AN/AN/A
9/30/201738,5894,489N/AN/AN/A
6/30/201738,3615,268N/AN/AN/A
3/31/201738,9116,121N/A6,400N/A
12/31/201640,48711,633N/AN/AN/A
9/30/201638,11010,961N/AN/AN/A
6/30/201636,5399,388N/AN/AN/A
3/31/201633,4745,504N/A3,706N/A
12/31/201532,9977,367N/AN/AN/A
9/30/201532,3257,247N/AN/AN/A
6/30/201531,5285,207N/AN/AN/A

アナリストによる今後の成長予測

収入対貯蓄率: BIOCONの予測収益成長率 (年間47.6% ) は 貯蓄率 ( 6.9% ) を上回っています。

収益対市場: BIOCONの収益 ( 47.6% ) はIndian市場 ( 16.3% ) よりも速いペースで成長すると予測されています。

高成長収益: BIOCONの収益は今後 3 年間で 大幅に 増加すると予想されています。

収益対市場: BIOCONの収益 ( 13.1% ) Indian市場 ( 10.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: BIOCONの収益 ( 13.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BIOCONの 自己資本利益率 は、3年後には低くなると予測されています ( 5.7 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/21 06:05
終値2026/05/21 00:00
収益2026/03/31
年間収益2026/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Biocon Limited 18 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。39

アナリスト機関
Rohit Bhat360 ONE Capital Market Private Limited
Meeta ShettyAsian Markets Securities Private Limited
Harith AhamedAvendus Spark